Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Trial of Bendamustine/Treanda®, Rituximab, Etoposide, and Carboplatin for Patients With Relapsed or Refractory Lymphoid Malignancies and Select Untreated Lymphomas (TREC)

NCT01165112 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT01165112
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01165112 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Trial of Bendamustine/Treanda®, Rituximab, Etoposide, and Carboplatin for Patients With Relapsed or Refractory Lymphoid Malignancies and Select Untreated Lymphomas (TREC)
Lead sponsor
University of Washington
Phase
Phase 1/2
Overall status
Completed
Start date
September 30, 2010
Completion date
June 30, 2015
Enrollment
48 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent adult diffuse large cell lymphoma, recurrent adult hodgkin lymphoma